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Abstract: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, affecting
at least 10% of women of reproductive age. PCOS is typically characterized by the presence of at
least two of the three cardinal features of hyperandrogenemia (high circulating androgen levels),
oligo- or anovulation, and cystic ovaries. Hyperandrogenemia increases the severity of the condition
and is driven by increased luteinizing hormone (LH) pulse secretion from the pituitary. Indeed,
PCOS women display both elevated mean LH levels, as well as an elevated frequency of LH pulsatile
secretion. The abnormally high LH pulse frequency, reflective of a hyperactive gonadotropin-releasing
hormone (GnRH) neural circuit, suggests a neuroendocrine basis to either the etiology or phenotype
of PCOS. Several studies in preclinical animal models of PCOS have demonstrated alterations in
GnRH neurons and their upstream afferent neuronal circuits. Some rodent PCOS models have
demonstrated an increase in GnRH neuron activity that correlates with an increase in stimulatory
GABAergic innervation and postsynaptic currents onto GnRH neurons. Additional studies have
identified robust increases in hypothalamic levels of kisspeptin, another potent stimulator of GnRH
neurons. This review outlines the different brain and neuroendocrine changes in the reproductive
axis observed in PCOS animal models, discusses how they might contribute to either the etiology or
adult phenotype of PCOS, and considers parallel findings in PCOS women.
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1. Introduction
Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder and a leading cause
of infertility, affecting at least 10% of reproductive-age women [1]. According to the Rotterdam criteria,
for a diagnosis of PCOS, women have to exhibit two out of the three cardinal features: (1) oligo- or
anovulation, (2) clinical and/or biochemical hyperandrogenism, and (3) polycystic ovaries [2]. In a
large number of cases, PCOS is also frequently associated with a metabolic phenotype, including
insulin resistance, increased adiposity, and cardiovascular diseases [3]. There is still no cure for PCOS,
as the symptomology is complex and varied, and the etiology of the disease remains unknown.
The reproductive abnormalities in PCOS women are thought to be the consequence of the high
androgens and luteinizing hormone (LH) levels [4–6]. PCOS women not only have higher basal
LH levels but also exhibit an increased number of LH pulses (i.e., pulse frequency) [4,7], together
contributing to the abnormally high LH levels. This is of importance, because the elevated LH levels
drive sex steroid (androgen and estrogen) synthesis by the ovarian theca cells and thus contribute
to hyperandrogenemia in PCOS. Gonadotropin-releasing hormone (GnRH) neurons in the forebrain
and preoptic area of the hypothalamus are the final node integrating all afferent signals to stimulate
the pulsatile secretion of pituitary gonadotropins, LH and follicle-stimulating hormone (FSH) [8].
The pulsatile release of GnRH by hypothalamic GnRH neurons regulates LH and FSH levels [9].
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Hence, abnormal LH secretion, especially in terms of altered LH pulse frequency, strongly points to
hyperactive GnRH pulse secretion from the brain.
The secretion of GnRH from the brain is itself regulated by a number of upstream neural and
endocrine factors that contribute to both the timing and magnitude of GnRH secretion. Such regulators
include hypothalamic populations of neurons expressing kisspeptin and gamma aminobutyric acid
(GABA), amongst others. Whether any of these afferent regulators of GnRH neurons are themselves
altered in PCOS remain unclear, but if so, may form the underlying basis for the hypersecretion of
GnRH and LH in this disorder. Furthermore, direct action of androgens in the brain is thought to
contribute to the manifestation of some PCOS traits [10]. This was demonstrated in a preclinical model
of PCOS where neuron-specific deletion of androgen receptor (AR) prevented ovulatory dysfunction
and reversed the increased adiposity induced by postnatal exposure to androgens [10]. Thus, increased
androgen signaling in the brain may be a potential mechanism in the pathophysiology of PCOS.
Over the last decade, there have been several studies providing genetic evidence to support
the importance of abnormal gonadotropin secretion and signaling in hyperandrogenemia and PCOS
traits. A recent study showed a strong association of LH and LHR gene polymorphisms with the
occurrence of PCOS [11]. In addition, there have been genome-wide association studies (GWAS) that
have identified variants in or near the LH/choriogonadotropin receptor (LHCGR) and FSH receptor
(FSHR) genes, as well as a variant in the FSHβ (β-subunit of FSH) gene [12–14]. The latter gene variant
results in the mutation of FSHβ, which causes FSH deficiency and is associated with high LH levels
and impaired folliculogenesis in the ovary [15]. Thus, identification of susceptibility loci in these genes
in PCOS women suggests that LH, LHCGR, FSHβ and FSHR genes may be involved in the etiology or
pathology of PCOS.
Several clinical studies have also implied a neuroendocrine basis to PCOS by demonstrating a
positive correlation of PCOS occurrence and psychiatric disorders. In particular, there is a higher
prevalence of PCOS in women with bipolar disorder (BPD) [16], thought to be associated with the
effect of neurotransmitter imbalance on the neuroendocrine axis regulating reproduction. Similarly,
there is a greater incidence of PCOS in women with epilepsy [17,18]. This is associated with transient
increases in LH, FSH and prolactin levels [19], which is reflective of altered hypothalamic-pituitary
function that might contribute to PCOS. Furthermore, there is a significant difference in the
occurrence of PCOS in women treated with valproate, a drug used to treat epilepsy and BPD [20–22].
Valproate acts by increasing GABA levels and can alter neuron firing by blocking voltage-gated ion
channels [23]. Hence, changes in GABA levels and action might be directly or indirectly modifying
the hypothalamus-pituitary-gonadal (HPG) axis, a possibility discussed more in later sections. Taken
together, these correlative relations also point to changes in the neuroendocrine axis as a possible
contributing factor to the etiology of PCOS.
This review will highlight the insights gained into the neuroendocrine mechanisms underlying
PCOS, focusing primarily on data gleaned from preclinical animal models of PCOS. First, we will
briefly introduce the various PCOS animal models and summarize their neuroendocrine reproductive
traits, focusing on gonadotropin and sex steroid levels. Following that, we will review recent findings
on brain and neuroendocrine alterations at the cellular, molecular, and physiological levels, in various
PCOS research models, and discuss how this may relate to the human PCOS condition.
2. Preclinical Models of PCOS
2.1. Need for Preclinical Animal Models
PCOS is a highly complex, multifactorial disorder with a range of both reproductive and, often,
metabolic abnormalities. Due to its different phenotypes and range of manifestations, it is extremely
challenging to identify the causes or underlying biological alterations of PCOS. In addition, limitations to
clinical studies in terms of trial design, logistics, and ethics, create challenges for progress in identifying
the etiology of PCOS. Furthermore, whereas ovarian and metabolic parameters are somewhat easier to
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assess, it is extremely challenging to investigate in vivo alterations in brain anatomy and function in
humans, including PCOS women. Therefore, the establishment of preclinical animal research models
has been highly beneficial in shedding light on potential causes and, in particular, neuroendocrine
mechanisms underlying PCOS. Most of the PCOS animal models are based on the androgen excess
and corresponding infertility seen in PCOS women and aim to mimic these parameters. While the
various animal models may not absolutely represent true PCOS, the models recapitulate many of the
phenotypes of the disease, allowing for investigators to identify possible underlying cellular, molecular,
and physiological alterations that may be occurring in the actual PCOS disorder (Table 1). Thus, the
preclinical models can be referred to as PCOS-like, but this does not diminish their value and merit for
understanding and testing what may be happening mechanistically in PCOS women, with the hopes
of identifying novel avenues for future therapeutics for the disorder.
2.2. Prenatally Androgenized Animals
One commonly studied hypothesis as to the origins of PCOS is fetal exposure to high androgen
levels during prenatal development [24]. This hypothesis is built on reports showing that (1) women
with PCOS have higher androgen levels during pregnancy compared to healthy pregnant women [25,26]
and (2) there is a high occurrence of PCOS in daughters from PCOS women. These observations
led to the development of prenatally androgenized (PNA) models of PCOS in which exposure of
pregnant dams to exogenous testosterone (T) or dihydrotestosterone (DHT) during late gestation
leads to a PCOS-like phenotype of the female offspring in adulthood. This PNA paradigm has been
performed in several species, including rodents, sheep, and rhesus monkeys [27–34]. Female PNA
rodents, sheep, and monkeys all exhibit hyperandrogenemia in adulthood. These animals also have
other reproductive and some metabolic abnormalities seen in PCOS. In particular, adult PNA rats,
generated with prenatal exposure to either T or DHT, have high mean LH levels and LH pulse frequency,
along with impaired estradiol positive feedback [35,36]. Similarly, adult PNA mice, generated with
prenatal DHT exposure, also display increased LH pulse secretion and impaired steroid hormone
negative feedback [29]. These PNA mice also have disrupted estrous cycles, atretic ovarian follicles,
and thecal cell hyperplasia [27,28,30]. Likewise, PNA monkeys prenatally exposed to testosterone
propionate display polycystic ovaries and increased adiposity [32], and also have high LH levels
and impaired negative feedback [31]. Finally, PNA sheep also develop PCOS-like reproductive and
metabolic phenotypes in adulthood, with high mean LH levels and rapid LH pulse frequency, along
with impaired steroid negative feedback [34,37].
2.3. Prenatal Treatment with AMH
In addition to prenatal treatment with exogenous androgens, a new PCOS mouse model has recently
been developed utilizing prenatal exposure to exogenous anti-müllerian hormone (AMH) [38]. AMH,
secreted from the ovaries, is increased in PCOS women and remains elevated during pregnancy [38].
Exogenous AMH has been demonstrated to stimulate GnRH neurons [39] and, hence, exposure to
elevated AMH is thought to be able to drive enhanced reproductive hormone (GnRH and LH) secretion.
Adult female mice that were exposed to elevated AMH in utero (PAMH mice) exhibit a reproductive
phenotype similar to PNA mice, including increased LH pulse frequency, increased androgen levels,
and disrupted estrous cyclicity [38]. In this model, the elevated AMH is hypothesized to drive increased
GnRH neuron activity in the mother, which in turn, drives increased LH secretion and increased
androgen synthesis, leading to a fetal environment with androgen excess (coming from the mother).
Therefore, the PAMH mice display a similar phenotype to PNA mice, perhaps because they are both
being exposed to elevated androgens during prenatal life. However, whether these two PCOS models
are indeed working through the same cellular, molecular, and physiological pathways remains to
be determined.
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Table 1. Characteristics of polycystic ovary syndrome (PCOS) and alterations in the neuroendocrine axis in preclinical PCOS animal models.
Parameter Prenatally Androgenized Animals (PNA) Postnatally Androgenized Animals Letrozole Treated Animals Clinical Data
Hyperandrogenemia
Mouse—Yes Mouse, Rat—High dihydrotestosterone
(DHT) due to exogenous DHT
treatment, but no increase in
testosterone (T)
Mouse—Yes
Yes (60% according to the
Rotterdam criteria)
Rat—Yes Rat—Yes
Sheep—Yes - -
Monkey—Yes - -
Luteinizing hormone (LH) levels
Mouse—High + ↑pulse frequency Mouse—No change Mouse—High High LH pulse frequency and
amplitudeRat—High + ↑pulse frequency Rat—No data Rat—High
Sheep—↑↓ (Conflicting reports) - - -
Monkey—High - - -
Negative feedback
Mouse—Impaired Mouse—No data Mouse—No data Need higher doses of Estradiol and
progesterone to decrease LH to
similar levels in healthy women
Rat—No data Rat—No data Rat—No data
Sheep—Impaired - -
Monkey—Impaired - -
GnRH/GnRH neurons
Mouse (PNA)—↑GnRH firing rate; ↑GABAergic
inputs to GnRH neurons; ↑GABAergic postsynaptic
currents Mouse (PAMH)—↑GnRH firing rate;
↑GABAergic inputs to GnRH neurons
Mouse—No data Mouse—No data
No data
Rat—No data Rat—No data Rat—No data
Sheep—No data - -
Monkey—No data - -
Kisspeptin/Kisspeptin neurons
Mouse—No data Mouse—No data Mouse—No data
Positive correlation between
kisspeptin and LH levels; NK3R
antagonist treatment decreased LH
and T levels in women with PCOS
Rat—↑Kiss and NKB positive cells in ARN; ↑Kiss1 and
Tac2 mRNA levels
Rat—↓Kiss1 mRNA in the
hypothalamus ↓Kiss-ir cells in ARN Rat—↑ARN Kiss cells
Sheep—No change Kiss cells, but ↑ in cell size of ARN
Kiss cells; ↓excitatory glutamatergic inputs to Kiss cells - -
Monkey—No data - -
GABA/GABA neurons
Mouse—↑GABAergic inputs from ARN to GnRH
neurons; ↓Progesterone receptor in ARN GABA
neurons
Mouse—No data Mouse—No data
Increased GABA in CSF of PCOS
womenRat—No data Rat—No data
Rat (LET by oral gavage)—↓GABA
mRNA levels in several brain regions
including the hypothalamus;
Co-administration of GABA with LET
decreased T levels and body weight
Sheep—No data - -
Monkey—No data - -
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2.4. Postnatally Androgenized Animals
Another preclinical PCOS model is generated by chronic exposure to androgens from the
peripubertal period onward. Rodents, postnatally exposed to androgens, typically DHT, around the
time of puberty, develop some features of a PCOS-like phenotype, though not as complete as the
PNA models. Postnatal androgenized female rodents demonstrate metabolic symptoms, including
increased adiposity and insulin resistance, and also display polycystic ovaries and disrupted estrous
cycles [40,41]. However, in contrast to PNA animals, PAMH mice, and PCOS women, postnatally
androgenized animals do not have high LH secretion; in fact, they have greatly reduced LH levels [42].
There are also postnatal rodent models treated with dehydroepiandrosterone (DHA/DHEA),
although the findings in these models are conflicting, with regards to the reproductive phenotype
and LH levels. In one study, mice postnatally treated with dehydroepiandrosterone (DHA/DHEA)
displayed significantly elevated LH levels, however these mice did not display any reproductive
phenotypes such as polycystic ovarian morphology or disrupted estrous cycles [40]. In another study
in rats, postnatal DHA treatment disrupted estrous cycles and ovarian follicle development [43,44].
However, these DHA-treated rats displayed lower LH levels, in contrast to the PCOS condition in
women. The main difference between these two DHA/DHEA studies, besides the species, was the
duration of treatment. The study in mice implanted a pellet at PND 21 (prepuberty) for 90 days [40],
whereas the rats were given DHEA either for 15 days from PND 21 (prepuberty) [44] or for 20 days
from PND 55 (adults) [43]. Overall, the typically reported decreased LH levels in DHT and DHA
postnatal models suggests that their neuroendocrine circuits are not altered similarly to that of PCOS
women. Thus, these postnatal androgen models perhaps better represents an “androgen negative
feedback” model rather than PCOS (at least from a neuroendocrine reproductive perspective).
2.5. Aromatase Inhibition Models
PCOS traits can also be induced by postnatal treatment with letrozole (LET), a non-steroidal
aromatase enzyme inhibitor. Chronic LET treatment in rats from puberty to adulthood (5 or 10 weeks in
total duration) disrupted estrous cycles, ovarian function, and increased both T and LH, mimicking the
reproductive symptoms of PCOS [45,46]. Recently, another LET model was developed by administering
LET to rats by oral gavage [47]. The treated rats had disrupted estrous cycles, arrested follicular
development, and high T and LH levels. They also exhibited a strong metabolic phenotype, with
increased body weight and glucose intolerance [47]. Similar to LET rats, chronic LET treatment in mice,
initiated peri-pubertally for 5 weeks, induced both metabolic and reproductive abnormalities [48]. LET
mice displayed disrupted estrous cycles, polycystic ovaries, and elevated LH and T levels, along with
increased adiposity and glucose intolerance, thereby recapitulating both the metabolic and reproductive
traits observed in many PCOS women [48]. In addition to the elevated T and LH levels, there was also
a decrease in FSH [48]. It is unclear if the elevated LH levels are due to impaired negative feedback
owing to reduced estradiol (E2) or heightened androgen action or both. These findings are consistent
with elevated T and LH levels in some PCOS women with low E2 levels. Due to the elevated LH
levels and strong reproductive phenotype in all LET models, these models are useful to study possible
changes in reproductive neural circuits in PCOS-like conditions.
In general, the LET models in rats and mice tend to induce an overweight or obese PCOS-like
phenotype, in contrast to the PNA model which has weaker or absent metabolic phenotype. Thus,
the LET model may nicely represent a PCOS condition with a corresponding metabolic dysfunction,
whereas the PNA model may better represent the lean PCOS condition. This is important, as PCOS
women exhibit a range of features and not all PCOS cases may be caused by the same underlying
alterations. Thus, having different animal models for different PCOS phenotypes may be informative
to providing mechanistic insight into each unique PCOS “subtype”. It also means that the changes and
impairments identified in the various PCOS models need not be the same, and discrepancies between
models may in fact be related to different PCOS subtype etiologies or adult phenotypes.
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3. Cellular and Molecular Mechanisms Contributing to the PCOS Neuroendocrine Phenotype
3.1. Implications of GnRH and LH Pulse Frequency vs. Amplitude
As stated earlier, the androgen excess observed in PCOS is thought to be a downstream result of
the increased LH levels. Many clinical studies have reported an increase in both the frequency and
amplitude of LH secretion in PCOS women [4–6]. As detailed in Section 2, and, consistent with the
clinical findings, there is also an increase in mean LH levels in PNA [30–32,35,37,42,49,50], PAMH [38]
and LET [45,46,48,51] models of PCOS. Some of the studies in PNA and PAMH models have gone
beyond single, one-off measures of LH to assess repeated LH measures over time, identifying clear
increases in LH pulse frequency [30,35,36,38] and LH pulse amplitude [37]. However, this information
is missing in the postnatally treated DHT and LET models, and studies performing multiple blood
sampling over several hours in these models are needed to assess possible changes in LH pulse
frequency and amplitude. Nevertheless, the overall high LH levels seen in PCOS women and most
preclinical PCOS animal models point to an abnormal hyper-activated hypothalamic-pituitary function.
Because the amplitude of LH pulses can be regulated at both the level of the brain (GnRH output) or
pituitary gonadotrope, alterations in basal LH levels or LH pulse amplitude may implicate changes
occurring at either tissue. However, frequency of LH pulses are entirely due to the timing of GnRH
pulse secretion, which itself may be dictated by upstream “GnRH pulse generator” alterations [52] or
by intrinsic changes in GnRH neurons themselves. The fact that PCOS women exhibit alterations in
LH pulse frequency directly implicates upstream changes in GnRH pulse frequency and its neural
network. In the next sections, we will highlight evidence supporting the likelihood of changes in
the brain, specifically in GnRH neurons and afferent hypothalamic GABA and/or kisspeptin neurons,
in contributing to the neuroendocrine mechanisms underlying PCOS.
3.2. GnRH Neurons
The pulsatile release of GnRH at the median eminence controls the frequency of LH pulse secretion
by the anterior pituitary. In addition to controlling the timing of LH secretion (i.e., pulse frequency),
GnRH also modulates gonadotropin subunit mRNA expression and LH synthesis [53–55], thereby
contributing to the absolute amount of LH released at any given time (i.e., basal levels and also,
pulse amplitude). Women with PCOS have high LH pulse frequency and amplitude [4,7]. The latter
implicates changes in either the pituitary or the brain, or both. In contrast, the former reflects an
increase specifically in the brain, either in GnRH neurons themselves or upstream controllers of
GnRH secretion.
In line with the hypothesis for altered brain function, studies in PNA female mice have shown
that GnRH neuron action potential firing activity is increased compared to that in control females [56].
In addition, there is an increase in both frequency and size of GABAergic postsynaptic currents (PSCs)
to GnRH neurons in PNA females, suggesting an enhanced GABAergic drive to GnRH neurons.
In congruence, another study demonstrated an increase in GABAergic synapses on GnRH neurons in
PNA mice [30]. Similarly, in female PAMH mice, there was an increase in GnRH neuron firing and this
correlated with an increase in number of GABA inputs onto GnRH neurons [38]. These findings, taken
together along with GABA being excitatory to GnRH neurons through activation of GABAA receptors,
suggest that GnRH neurons’ hyperactivity drives the increased LH secretion seen in these PCOS-like
models [57].
Besides the increase in excitatory GABAergic signals to the GnRH neurons, a decrease in inhibitory
steroid hormone feedback is also a suggested cause for increased GnRH activity. To support this,
it has been shown that PCOS women need a higher dose of estradiol and progesterone to achieve a
similar reduction in mean LH levels, LH pulse frequency, and LH pulse amplitude as control healthy
women [58]. There is also compelling evidence of impaired steroid hormone feedback in the PNA
PCOS model [29,30]. PNA mice displayed a blunted LH response after ovariectomy and estradiol
(E2) treatment, implicating impaired E2 negative feedback control of GnRH/LH secretion in PNA
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mice. Since GnRH neurons only express estrogen receptor (ER) β [59] and not the classical ERα [60] or
androgen receptor (AR) [61], which are the main receptors mediating negative feedback, the impaired
steroid feedback is likely mediated by afferent neurons. Thus, alterations in afferent neurons in the
GnRH neural circuit that express steroid hormone receptors may lead to the hyperactivity of GnRH
neurons. This will be discussed more in Sections 3.3 and 3.4.
3.3. GABAergic Neurons
An important neuron population in the GnRH neural circuit are GABA cells in the medial basal
hypothalamus. In the forebrain and many other areas of the brain, GABA is the main inhibitory
neurotransmitter. However, due to the high intracellular chloride concentration in GnRH neurons,
GABA actually excites these neurons rather than inhibits them. GABA’s stimulation of GnRH neurons
occurs through the GABAA receptor [57].
Recent findings have shown that levels of GABA are increased in the cerebrospinal fluid of PCOS
women [62]. Given GABA’s stimulatory actions on GnRH neurons, these elevated CSF levels of GABA
might contribute to the enhanced GnRH secretion in PCOS women, although this remains speculation
at present. More convincingly, in studies in the PNA and PAMH mouse, GABA neuron axon inputs to
the GnRH neurons were found to be increased [30,38]. Furthermore, the increased GABA fiber inputs
originated specifically from cells in the arcuate nucleus (ARN) [30]. As already noted above, studies in
PNA mice also reported an increase in GABAergic postsynaptic currents onto the GnRH neurons [28].
These findings highlight a possible role of GABA neurons in the hyperactivity of GnRH neurons in
PCOS, at least in the PNA and PAMH models.
In addition to changes in GABA signaling to the GnRH neurons, the regulation of GABA neurons
themselves is also altered in PCOS animal models. The ARN GABA neurons of PNA females exhibit a
decrease in expression of progesterone receptor (PR), perhaps contributing to the impaired steroid
hormone feedback seen in this PCOS model [29,30] and matching the decreased progesterone feedback
phenotype in some PCOS women [63]. The impaired progesterone feedback in PCOS women was also
demonstrated in a study where PCOS women needed higher levels of progesterone to decrease LH
compared to healthy women [58]. In the LET mouse model of PCOS, there is also a decrease in PR
mRNA expression in the ARN region, as quantified by qPCR in mediobasal hypothalamic punches [48].
Further studies are needed to assess the specific neuron types that have decreased PR expression
in the ARN region and determine if it is also the GABA neurons, as in the PNA mice; nonetheless,
the diminished PR levels in LET mice suggest the possibility of diminished progesterone feedback
in this model as well. Thus, GABA neurons, specifically ARN GABA neurons, might be a critical
population to mediate normal progesterone negative feedback to the GnRH system, which is altered in
a PCOS-like condition.
Surprisingly, apart from the PNA and PAMH mice, there are almost no reports of ARN GABA
levels, number of GABA neurons, or GABA signaling to GnRH neurons in other animal models of
PCOS. Recently, in a different LET model also exhibiting high LH levels, where rats received LET
by oral gavage, there was a decrease in GABA mRNA levels in several brain regions, including the
hypothalamus [47]. In this same LET model, co-administration of GABA with LET decreased body
weight and T levels compared to that of animals given just LET [64]. These findings would suggest
that GABA is actually inhibitory to the reproductive axis, and that PCOS-condition has diminished
inhibitory GABA signaling. This contrasts the stimulatory GABA story in the PNA mouse model, but
the two findings are not necessarily in conflict, as GABA can act on multiple neuron populations in
the brain and can be stimulatory in some (GnRH neurons) and inhibitory in others. The decrease is
GABA levels could lead to increased activity of afferent neurons such as kisspeptin neurons, which are
stimulatory to GnRH neurons. However, this is just speculation and further investigation is needed to
test this hypothesis. Thus, where GABA is acting—or not acting—in most of the in vivo studies is not
always clear and remains to be determined.
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3.4. Kisspeptin Neurons
Kisspeptin, encoded by the Kiss1 gene, is a 54-amino-acid protein that acts through the membrane
receptor Kiss1r [65]. Kisspeptin is a potent stimulator of GnRH neurons [66]. In PCOS women, there is
a positive correlation of circulating kisspeptin levels in the blood with the high circulating LH levels,
though the source of this circulating kisspeptin (brain, liver, pancreas, adipose, gonad, etc.) is not
immediately clear [67,68]. These findings, along with data from kisspeptin or Kiss1r knockout studies
demonstrating an indispensable role of kisspeptin and Kiss1r in GnRH/LH secretion [69,70], suggest
that kisspeptin-Kiss1r signaling may be a good candidate for an altered neural mechanism in the
PCOS condition.
Kisspeptin is expressed in several tissues, including the brain and several peripheral tissues, but
studies have determined that neural kisspeptin signaling specifically to GnRH neurons is the primary
mode by which kisspeptin stimulates the reproductive axis [71,72]. Within the brain, kisspeptin is
primarily expressed in the hypothalamic arcuate nucleus (ARN) and the anteroventral periventricular
nucleus and periventricular nucleus continuum (AVPV/PeN), regions implicated in the regulation of
GnRH secretion [65,73]. Lower degrees of kisspeptin expression occur in the medial amygdala [74], bed
nucleus of the solitary tract (BNST), and lateral septum [75], but the roles of these extra-hypothalamic
kisspeptin neurons remains unknown. The two hypothalamic kisspeptin populations are thought to
serve different roles, with the ARN cells being involved in stimulating GnRH/LH pulses in both females
and males [52], while the AVPV/PeN cells regulate the preovulatory GnRH/LH surge in females [65].
ARN kisspeptin neurons are unique in terms that they co-express Neurokinin B (NKB) and Dynorphin
(Dyn), and hence, are known as the KNDy neurons [76]. Both NKB and Dyn play a role in modulating
kisspeptin neuron activity and downstream regulation of GnRH/LH secretion [77]. NKB, encoded
by the TAC3 gene in humans and Tac2 gene in rodents, acts via the NKB receptor (NK3R; encoded
by TACR3 gene in humans and Tacr3 in rodents) [78], and mutations in either TAC3 or TACR3 are
associated with hypogonadotropic hypogonadism [79]. Dyn acts on the kappa opioid receptor to
decrease LH secretion [80], likely mediated via inhibition of KNDy neuron activity. In non-human
primates, kisspeptin and NKB-NK3R signaling have been shown to increase GnRH release [81].
ARN KNDy neurons are negatively regulated by sex steroids, via androgen and estrogen receptor
pathways [82,83], and are likely responsible for driving the hyperactive GnRH secretion pattern after
removal of sex steroids via gonadectomy. On the other hand, AVPV/PeN kisspeptin neurons are
positively regulated by elevated estradiol [82,83] and progesterone [84] levels leading up to the time of
ovulation. In humans, kisspeptin neurons are present in the infundibular nucleus of the hypothalamus
of both sexes [85], and in the rostral periventricular zone of females only [86]. These periventricular
zone kisspeptin neurons may be analogous to the AVPV/PeN kisspeptin neurons seen in rodents
known to mediate positive steroid feedback. Because PCOS women display abnormal increases in LH
pulse secretion, most PCOS animal studies have focused on the ARN kisspeptin neurons, homologous
to the human infundibular kisspeptin neurons.
In PNA female rats, there is a significant increase in the number of ARN kisspeptin- and NKB
positive cells, as measured with immunohistochemistry, compared to control females [42]. Consistently,
another study in PNA rats reported increased Kiss1 and Tac2 (the gene for NKB) mRNA expression in
the ARN [36]. In PNA sheep, there is no increase in the number of kisspeptin cells; however, there is an
increase in the size of kisspeptin neurons [87]. Because kisspeptin normally activates GnRH neurons,
the observed increase in the number of kisspeptin cells or Kiss1 mRNA could be a potential cause of
increased GnRH neuron activity and LH secretion seen in this PNA model of PCOS.
In postnatally treated models of PCOS, the effect on kisspeptin neurons has been investigated
in animals treated with DHT or LET. In rats postnatally treated with DHT, there was a decrease in
Kiss1 mRNA in the hypothalamus, as well as a decrease in kisspeptin-ir cells in the ARN [88]. This is
congruent with a decrease in LH compared to controls in this model, rather than an increase in LH
as observed in PCOS [42]. On the other hand, in the rat LET PCOS model, in which females show
Med. Sci. 2019, 7, 84 9 of 16
high LH levels, there is a corresponding increase in the number of ARN kisspeptin cells compared to
control females [89].
Overall, the number of kisspeptin cells and the amount of Kiss1 and Tac2 mRNA in the ARN
positively correlate with LH levels in rodent PCOS models. Since kisspeptin stimulates GnRH neurons
and NKB stimulates kisspeptin neurons via the NK3 receptor [90], the findings in the PCOS models
suggest a role of the ARN KNDy neurons in driving GnRH hyperactivity and downstream elevated
LH pulse secretion. In support of this, a clinical trial in PCOS women recently attempted to target
KNDy neurons and decrease their activity to reduce LH secretion. This study treated PCOS women
with an NK3 receptor antagonist [91] for 28 days and found that the treatment significantly reduced
LH pulsatility and, subsequently, serum T concentrations. This was a phase 2 clinical trial and,
therefore, did not evaluate long-term, post-treatment serum LH or T levels or ovulation; nonetheless, it
demonstrated that the kisspeptin-NKB system is a promising therapeutic target to lower LH and T in
PCOS women.
3.5. Contributions and Effects of Androgen Signaling in the Brain
Given the typically prevalent high circulating androgen levels in PCOS women, it is essential to
dissect the contribution of such hyperandrogenemia to the pathophysiology of PCOS. An outstanding
debate is whether the elevated androgens in PCOS women are merely a downstream endocrine
response to hyperactive GnRH and LH secretion driving the ovary, or do the elevated androgens
themselves act in the brain (or pituitary) during development and/or adulthood to sculpt and maintain
the hypersecretion of GnRH and LH? Indeed, the mechanisms by which elevated androgens may
mediate the changes in the neuroendocrine axis still remain unclear, and deciphering neural targets of
androgen action may provide important information for development of treatments for PCOS. In PCOS
women, treatment with flutamide decreased LH levels after E2 and P administration similar to that of
control women [92]. This is of particular importance, because the same E2 and P administration failed
to lower LH in PCOS women with no flutamide treatment [58], suggesting that hyperandrogenemia
contributes to impaired steroid (E2 or P) hormone feedback in PCOS. Consistent with these findings, a
recent study in the PNA PCOS model has shown that treatment with flutamide, an androgen receptor
antagonist, can reverse abnormal GnRH neuron morphology, decrease T levels, and restore estrous
cyclicity in PNA mice [93], suggesting that hyperandrogenemia is causing, directly or indirectly, some
of the GnRH abnormalities (other aspects of GnRH physiology or upstream afferent circuits were
not studied). This finding also highlights the promise of anti-androgenic drugs in the treatment of
PCOS. However, since this study administered flutamide peripherally, it is not clear whether the
androgen blockade occurring directly in the brain or other tissues was responsible for restoring these
reproductive parameters, and if it was in the brain, in what specific cell targets? In support of the
importance of androgen signaling specifically in the brain, a recent study in postnatally androgenized
mice showed that androgen receptor (AR) knockout in the brain (using Cre/lox technology) improved
ovarian morphology and function and decreased adiposity [10]. In that study, AR was assumed to
be deleted in all neurons, and thus the exact brain region(s) and specific neuron types involved still
remain to be elucidated. Nonetheless, these studies demonstrate that androgen actions in the brain
may play a role in the manifestations of PCOS and that androgen-induced alterations in the GnRH
neural network are likely to be important in the pathogenesis of many cases of PCOS.
One major caveat to the theory that androgens are inducing hyper GnRH secretion is that
androgens typically have been shown to provide negative feedback on the HPG axis, including in
females. Thus, one would expect high androgen levels to provide heightened negative feedback and
lower GnRH/LH secretion, rather than reducing negative feedback and facilitating increased GnRH/LH
secretion. Indeed, androgen treatments not only reduce LH secretion in vivo, but also lower ARN
Kiss1 levels [82,94], further driving decreased GnRH output. This discrepancy with known negative
feedback actions of androgen actions needs to be resolved in future studies postulating a role for
androgens in actually promoting the hypersecretion of GnRH in PCOS.
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4. Concluding Remarks and Perspectives
Despite its high prevalence, there is still no cure for PCOS. Clinical studies in the past few decades
have significantly contributed to characterization of the condition and have also shed light on the
different phenotypes and its occurrence. However, due to challenges associated with logistics and
ethical issues, there has been limited progress in identifying the root causes of PCOS, especially at the
level of the brain and pituitary. Development of preclinical animal models has been extremely helpful
in addressing the hypotheses around the neuroendocrine contributions to PCOS. These animal models
have established an important role of the brain in the possible pathogenesis of PCOS. Studies in PNA
and PAMH mice have clearly demonstrated the presence of a hyperactive GnRH system that drives the
increased LH levels in these PCOS-like conditions [29,30,38]. LET models of PCOS also nicely show
elevated mean LH levels in both rats and mice, although specific demonstration of increased frequency
of LH pulses in these LET models has yet to be reported.
This review has also touched on the possible contribution of afferent neurons, kisspeptin and
GABA neurons, to the hyperactivity of the GnRH neurons (Figure 1). However, it is to be noted that
there are still missing pieces of information in some models with regard to GnRH neurons and its
afferent neural network. Nonetheless, alongside clinical studies showing increased CSF GABA [62]
and blood kisspeptin [67,68] levels in PCOS women, and an improvement in T and LH levels after
treatment with a NK3R antagonist in PCOS women [91], the involvement of the neuroendocrine
axis in the pathogenesis of PCOS is becoming more convincing. However, there are still a number
of important unanswered questions that need addressing. Identifying specific neuron populations
and signaling factors altered in PCOS is key to the development of potential therapeutics. Besides
KNDy and GABA neurons, there may be other potential neurons involved in directly or indirectly
modulating GnRH neuron function that may be affected in PCOS. Since PCOS is often also a metabolic
disorder, with increased adiposity and impaired insulin sensitivity, it is likely that metabolic-sensitive
neurons (e.g., AgRP/NPY and POMC neurons) may also contribute to the neuroendocrine mechanisms
underlying PCOS. Thus, future studies investigating the contribution of other neuron populations
and the neuropeptides and neurotransmitters they release are needed to get a complete picture of the
neuroendocrine origins and adult phenotype of PCOS. In addition, identifying developmental time
periods during which these neurons and circuits are altered will provide important information about
“critical periods” for therapeutic targeting of these circuits.
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Figure 1. Changes in the brain and neuroendocrine reproductive axis in PCOS women and PCOS-like
animal models. Clinical studies demonstrate very high circulating LH levels in PCOS individuals,
and this is recapitulated in the prenatally androgenized (PNA) and letrozole (LET) preclinical animal
models. These high-frequency LH pulses contribute to thecal cell hyperplasia and stimulate increased
production and secretion of ovarian androgens, contributing to hyperandrogenemia. The elevated
LH levels and LH pulse frequency seen in PCOS and the PCOS animal models point to an upstream
hyperactive GnRH neural circuit. In PNA mice and mice prenatally treated with AMH (PAMH), there
is an increased firing rate of GnRH neurons. PNA mice also exhibit an increase in upstream GABAergic
postsynaptic currents (PSCs). There is also impaired sex steroid negative feedback observed in PNA
models and PCOS women, and this may be mediated by alterations in afferent hypothalamic GABA
neurons, at least in PNA mice. In relation to this, progesterone receptor (PR) expression is decreased
in ARN GABA neurons in PNA mice and in the mediobasal hypothalamus of LET mice. Alongside
GABA, there is also an increase in ARN KNDy cells and ARN Kiss1 and Tac2 mRNA levels in PNA and
LET PCOS models, possibly providing an increase in excitatory signals to GnRH neurons. Refer to
the article text for discussion on species differences and specific brain parameters that have not yet
been assessed in different models. [LH—luteinizing hormone; PNA—prenatally androgenized animals;
LET—letrozole-treated PCOS models; H—human/clinical data from PCOS women].
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